STOCKHOLM, June 16, 2018 /PRNewswire/ --
Waldenström's Macroglobulinemia (WM) is a rare type of blood cancer. SinceWM is rare, it is difficult to conduct large clinical studies and determine a standard treatment for the disease. Rituximab, a therapy used to treat other types of blood cancer, is effective and commonly used in treating WM, by itself or when given with
(Logo: http://mma.prnewswire.com/media/622259/EHA_Logo.jpg )
Presenter: Dr Meletios Dimopoulos
Affiliation: National and Kapodistrian University of Athens School of Medicine, Athens, Greece
Topic: MULTINATIONAL, RANDOMIZED PHASE 3 TRIAL OF IBRUTINIB-RITUXIMAB VS PLACEBO-RITUXIMAB IN PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA.
Abstract S852 will be presented by Meletios Dimopoulos on Saturday, June 16, 16:00-16:15 in Victoria Hall.
Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information check our Congress Media Guidelines here.
SOURCE European Hematology Association
Subscribe to our Free Newsletters!
Complex regional pain syndrome (CRPS) is rare chronic pain disorder usually involving an arm or ...
Polyarthritis refers to pain in four or more joints simultaneously due to various causes ranging ...
Gardner or Gardner''s syndrome, also known as familial adenomatous polyposis (FAP), is an autosomal ...View All